Daewon Pharmaceutical Co., Ltd. (KRX: 003220)

Daewon Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	593,945	526,952	478,885	354,176	308,501	317,828
Other Revenue	-	-0	-0	-0	0	-0
Revenue	593,945	526,952	478,885	354,176	308,501	317,828
Revenue Growth (YoY)	16.77%	10.04%	35.21%	14.81%	-2.93%	10.88%
Cost of Revenue	305,331	271,808	243,038	179,630	144,354	139,442
Gross Profit	288,614	255,144	235,847	174,546	164,147	178,385
Selling, General & Admin	235,198	207,704	173,719	144,585	135,522	128,515
Research & Development	12,961	9,010	12,646	-	-	10,244
Other Operating Expenses	3,408	2,951	2,320	8,009	2,080	1,932
Operating Expenses	257,527	222,911	192,943	155,243	140,168	143,410
Operating Income	31,087	32,233	42,904	19,303	23,979	34,976
Interest Expense	-8,655	-4,614	-3,683	-2,078	-1,182	-268.57
Interest & Investment Income	1,652	1,416	1,259	532.2	281.72	239.39
Earnings From Equity Investments	525.08	509.42	860.08	382.62	517.27	78.12
Currency Exchange Gain (Loss)	42.32	121.26	219.82	71.59	-91.69	1.45
Other Non Operating Income (Expenses)	222.78	672.88	23.15	906.98	-1,139	70.07
EBT Excluding Unusual Items	24,874	30,338	41,583	19,119	22,365	35,096
Gain (Loss) on Sale of Investments	557.9	-61.5	-752.76	-870.39	1,990	304.11
Gain (Loss) on Sale of Assets	-247.23	149.95	45.71	-0.86	2.34	-1.61
Asset Writedown	-6,030	-4,597	-2,154	-1,111	-715.77	-26.54
Pretax Income	19,155	25,830	38,722	17,136	23,642	35,372
Income Tax Expense	6,192	2,367	8,065	10,525	6,443	8,493
Earnings From Continuing Operations	12,963	23,463	30,657	6,611	17,198	26,879
Minority Interest in Earnings	3,056	453.67	1,287	378.15	441.9	409.54
Net Income	16,019	23,917	31,944	6,989	17,640	27,289
Net Income to Common	16,019	23,917	31,944	6,989	17,640	27,289
Net Income Growth	-38.70%	-25.13%	357.08%	-60.38%	-35.36%	14.93%
Shares Outstanding (Basic)	21	21	21	21	21	22
Shares Outstanding (Diluted)	22	22	22	21	21	22
Shares Change (YoY)	0.14%	-0.98%	3.09%	-0.58%	-1.06%	-0.01%
EPS (Basic)	756.15	1139.91	1509.75	329.36	826.54	1265.08
EPS (Diluted)	756.15	1110.44	1478.37	329.36	826.54	1265.08
EPS Growth	428.74%	-24.89%	348.85%	-60.15%	-34.66%	14.94%
Free Cash Flow	-13,963	39,446	18,405	18,309	13,605	-2,055
Free Cash Flow Per Share	-644.00	1821.12	841.34	862.87	637.47	-95.25
Dividend Per Share	300.000	300.000	-	194.175	155.340	233.405
Dividend Growth	-	-	-	25.00%	-33.45%	0%
Gross Margin	48.59%	48.42%	49.25%	49.28%	53.21%	56.13%
Operating Margin	5.23%	6.12%	8.96%	5.45%	7.77%	11.00%
Profit Margin	2.70%	4.54%	6.67%	1.97%	5.72%	8.59%
Free Cash Flow Margin	-2.35%	7.49%	3.84%	5.17%	4.41%	-0.65%
EBITDA	50,746	49,794	62,272	37,109	39,652	46,790
EBITDA Margin	8.54%	9.45%	13.00%	10.48%	12.85%	14.72%
D&A For EBITDA	19,658	17,561	19,368	17,805	15,674	11,814
EBIT	31,087	32,233	42,904	19,303	23,979	34,976
EBIT Margin	5.23%	6.12%	8.96%	5.45%	7.77%	11.00%
Effective Tax Rate	32.32%	9.16%	20.83%	61.42%	27.25%	24.01%
Advertising Expenses	-	29,701	27,199	26,272	23,013	23,037

Source: S&P Capital IQ. Standard template. Financial Sources.